T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ETFC
226
DELISTED
E*Trade Financial Corporation
ETFC
| $478M | 0.1% |
20,349,480
-1,193,971
| -6% | -$30.3M |
|
227
Burlington
BURL
$22.6B
| $477M | 0.1% |
7,153,492
+830,434
| +13% | +$48.8M |
|
228
Entergy
ETR
$49.7B
| $473M | 0.1% |
11,628,638
-7,798,776
| -40% | -$299M |
|
229
Bath & Body Works
BBWI
$3.81B
| $462M | 0.1% |
8,510,099
-569,439
| -6% | -$33.4M |
|
230
Palo Alto Networks
PANW
$313B
| $458M | 0.1% |
22,407,048
-23,847,888
| -52% | -$552M |
|
231
Nucor
NUE
$61.9B
| $457M | 0.1% |
9,258,613
-2,224,509
| -19% | -$108M |
|
232
Vail Resorts
MTN
$5.26B
| $457M | 0.1% |
3,302,594
-356
| -0% | -$47K |
|
233
Equinix
EQIX
$102B
| $450M | 0.1% |
1,161,560
+766,579
| +194% | +$268M |
|
234
Cummins
CMI
$87.1B
| $449M | 0.1% |
3,990,817
-265,794
| -6% | -$30.1M |
|
235
NRG Energy
NRG
$25.2B
| $447M | 0.09% |
29,842,025
+9,497,982
| +47% | +$141M |
|
236
Rayonier
RYN
$6.45B
| $442M | 0.09% |
18,581,057
+31,191
| +0.2% | +$716K |
|
237
Revvity
RVTY
$12.9B
| $441M | 0.09% |
8,411,413
+66,510
| +0.8% | +$3.5M |
|
238
United Airlines
UAL
$41B
| $438M | 0.09% |
10,678,068
-14,046,626
| -57% | -$665M |
|
239
Xylem
XYL
$28.8B
| $437M | 0.09% |
9,790,711
+15,620
| +0.2% | +$679K |
|
240
Gartner
IT
$11.8B
| $426M | 0.09% |
4,371,086
-1,097,517
| -20% | -$104M |
|
241
Analog Devices
ADI
$188B
| $425M | 0.09% |
7,504,886
+423,932
| +6% | +$24.3M |
|
242
Idexx Laboratories
IDXX
$46.2B
| $421M | 0.09% |
4,531,897
-274,491
| -6% | -$23.6M |
|
243
Pricesmart
PSMT
$5.33B
| $420M | 0.09% |
4,493,018
+494,090
| +12% | +$42.9M |
|
244
Chubb
CB
$134B
| $420M | 0.09% |
3,212,013
+330,141
| +11% | +$40.7M |
|
|
LVNTA
245
DELISTED
Liberty Interactive Corporation Series A Liberty Ventures
LVNTA
| $419M | 0.09% |
11,291,837
+3,163,973
| +39% | +$120M |
|
246
Neurocrine Biosciences
NBIX
$16.5B
| $418M | 0.09% |
9,194,854
-380,890
| -4% | -$17.5M |
|
247
CenterPoint Energy
CNP
$26.5B
| $418M | 0.09% |
17,406,924
-1,706,851
| -9% | -$37.7M |
|
248
Federal Realty Investment Trust
FRT
$10.1B
| $416M | 0.09% |
2,514,886
-161,594
| -6% | -$25.2M |
|
249
Amgen
AMGN
$224B
| $414M | 0.09% |
2,721,434
-102,804
| -4% | -$16M |
|
|
CTLT
250
DELISTED
CATALENT, INC.
CTLT
| $414M | 0.09% |
17,997,876
-452,589
| -2% | -$11.9M |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.